SNSE übertreffen die 12 der letzten 20Schätzungen.
60%
Nächster Bericht
Datum des nächsten Berichts
26. März 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$4.90
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
+35.36%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-20.97%
Sensei Biotherapeutics, Inc. Common Stock earnings per share and revenue
On 14. Nov. 2025, SNSE reported earnings of -3.62 USD per share (EPS) for Q3 25, beating the estimate of -4.19 USD, resulting in a 13.65% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -11.25% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -4.90 USD, with revenue projected to reach -- USD, implying an increase of 35.36% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Sensei Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Sensei Biotherapeutics, Inc. Common Stock reported EPS of -$3.62, beating estimates by 13.65%, and revenue of $0.00, 0% as expectations.
How did the market react to Sensei Biotherapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -11.25%, changed from $9.02 before the earnings release to $8.01 the day after.
When is Sensei Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 26. März 2026.
What are the forecasts for Sensei Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Sensei Biotherapeutics, Inc. Common Stock is expected to report EPS of -$4.90 and revenue of -- for Q4 2025.